Tm Bioscience licenses patents for CF (cystic fibrosis) gene test:
This article was originally published in Clinica
Executive Summary
Tm Bioscience has acquired a non-exclusive licence for cystic fibrosis (CF) gene mutation patents for use in its Tag-It mutation detection kit. The Tag-It CF test, the firm's flagship product, is currently being assessed by potential customers and is expected to reach the market in the third quarter of 2003, says the Toronto, Ontario company. The CF patents were licensed from The Hospital for Sick Children, also in Toronto, Ontario, and the University of Michigan, in Ann Arbor, Michigan. Other tests in the firm's pipeline include those for genetic mutations related to haematology, toxicology and other debilitating genetic disorders.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.